Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

2019362 citationsJournal Articlebronze Open Access

Authors

Audrey Simonaggio · Institut Gustave Roussy

Jean‐Marie Michot · Institut Gustave Roussy

Anne Laure Voisin · Institut Gustave Roussy

Jérôme Le Pavec · Hôpital Marie Lannelongue

Michael Collins · Assistance Publique – Hôpitaux de Paris

A. Lallart · Institut Gustave Roussy

Geoffray Cengizalp

Abstract

The risk-reward ratio for an anti-PD-1 or anti-PD-L1 rechallenge appears to be acceptable, although these patients require close monitoring; further investigation into rechallenge conditions through a prospective clinical trial is needed.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Oncology

Volume 5, Issue 9, pp. 1310-1310

DOI: 10.1001/jamaoncol.2019.1022

Field-Weighted Citation Impact: 21.60

Command Palette